Immunotherapies developer Scancell has launched a research programme focused on the development of a DNA vaccine candidate to protect from Covid-19.

The project will involve researchers from the University of Nottingham, Centre for Research on Global Virus Infections, the Biodiscovery Institute and Nottingham Trent University.

DNA vaccines by Scancell target dendritic cells to induce high avidity T-cells that identify and destroy diseased cells.

The company’s lead candidate is an ImmunoBody cancer vaccine, SCIB1, which demonstrated safety and five-year survival in malignant melanoma patients in Phase I/II clinical trials.

Scancell intends to develop a safe, cost-effective and scalable vaccine that could trigger durable T-cell responses as well as virus neutralising antibodies (VNAbs) against Covid-19 infection.

The T-cell plus antibody approach could deliver potent and long-lasting responses. The vaccine will be designed to act on the SARS-CoV-2 nucleocapsid (N) protein, as well as the main receptor-binding domain of the spike (S) protein.

As the N protein is present in many coronaviruses, the vaccine could generate protection against SARS-CoV-2 as well as any coronavirus strains arising in the future.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.